Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Virol
1994 Nov 01;6811:7178-87. doi: 10.1128/JVI.68.11.7178-7187.1994.
Show Gene links
Show Anatomy links
Functional characterization of Xenopus laevis p53: evidence of temperature-sensitive transactivation but not of repression.
Ridgway PJ, Soussi T, Braithwaite AW.
???displayArticle.abstract???
We have investigated the effect of Xenopus laevis p53 (Xp53) on transcription from a variety of promoters which are regulated by mouse p53 using a chloramphenicol acetyltransferase reporter system. Although Xp53 transactivated promoters that are up-regulated by mouse p53, it was unable to cause repression. This ability to transactivate gene expression was dependent on a temperature of 32 degrees C, and activity was lost at 37 degrees C. Temperature-sensitive transactivation was correlated with temperature-dependent binding of Xp53 to the adenovirus E1B58K protein. Despite the marked loss of transcriptional activation and binding to E1B58K at 37 degrees C, Xp53 was still capable of binding simian virus 40 large T antigen and inhibiting simian virus 40 origin-dependent DNA replication. These data show that Xp53 is temperature sensitive for N-terminal activities and suggest that the transactivation and repression "domains" of p53 are distinct.
Baker,
Suppression of human colorectal carcinoma cell growth by wild-type p53.
1990, Pubmed
Baker,
Suppression of human colorectal carcinoma cell growth by wild-type p53.
1990,
Pubmed Bargonetti,
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.
1991,
Pubmed Braithwaite,
Transactivation of the p53 oncogene by E1a gene products.
1990,
Pubmed Braithwaite,
Adenovirus E1b-58 kD antigen binds to p53 during infection of rodent cells: evidence for an N-terminal binding site on p53.
1991,
Pubmed Braithwaite,
Mouse p53 inhibits SV40 origin-dependent DNA replication.
,
Pubmed Braithwaite,
Ability of p53 and the adenovirus E1b 58-kilodalton protein to form a complex is determined by p53.
1989,
Pubmed Cullen,
Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.
1986,
Pubmed Diller,
p53 functions as a cell cycle control protein in osteosarcomas.
1990,
Pubmed Donehower,
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
1992,
Pubmed Dutta,
Inhibition of DNA replication factor RPA by p53.
1993,
Pubmed el-Deiry,
Definition of a consensus binding site for p53.
1992,
Pubmed Eliyahu,
Wild-type p53 can inhibit oncogene-mediated focus formation.
1989,
Pubmed Farmer,
Wild-type p53 activates transcription in vitro.
1992,
Pubmed Fields,
Presence of a potent transcription activating sequence in the p53 protein.
1990,
Pubmed Funk,
A transcriptionally active DNA-binding site for human p53 protein complexes.
1992,
Pubmed Ginsberg,
Wild-type p53 can down-modulate the activity of various promoters.
1991,
Pubmed Gorman,
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.
1982,
Pubmed Gorman,
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
1982,
Pubmed Hall,
High levels of p53 protein in UV-irradiated normal human skin.
1993,
Pubmed Harlow,
Monoclonal antibodies specific for simian virus 40 tumor antigens.
1981,
Pubmed Hartwell,
Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells.
1992,
Pubmed Hinds,
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
1990,
Pubmed Hinds,
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
1989,
Pubmed Hirt,
Selective extraction of polyoma DNA from infected mouse cell cultures.
1967,
Pubmed Hollstein,
p53 mutations in human cancers.
1991,
Pubmed
,
Xenbase Jackson,
Wild-type mouse p53 down-regulates transcription from different virus enhancer/promoters.
1993,
Pubmed Jenkins,
Cloning and expression analysis of full length mouse cDNA sequences encoding the transformation associated protein p53.
1984,
Pubmed Jenkins,
Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen.
1988,
Pubmed
,
Xenbase Kao,
Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.
1990,
Pubmed Kastan,
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
1992,
Pubmed Kuerbitz,
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
1992,
Pubmed Lane,
T antigen is bound to a host protein in SV40-transformed cells.
1979,
Pubmed Lane,
Cancer. A death in the life of p53.
1993,
Pubmed Levine,
The p53 tumour suppressor gene.
1991,
Pubmed Liu,
The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.
1993,
Pubmed Maheswaran,
Physical and functional interaction between WT1 and p53 proteins.
1993,
Pubmed Mercer,
Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression.
1991,
Pubmed Mercer,
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.
1990,
Pubmed Oliner,
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
1993,
Pubmed Pietenpol,
Tumour suppressor genes. No room at the p53 inn.
1993,
Pubmed Pilder,
The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs.
1986,
Pubmed Ragimov,
Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif.
1993,
Pubmed Raycroft,
Analysis of p53 mutants for transcriptional activity.
1991,
Pubmed Ridgway,
p53 confers a selective advantage on transfected HeLa cells.
1993,
Pubmed Sarnow,
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.
1982,
Pubmed Sleigh,
A nonchromatographic assay for expression of the chloramphenicol acetyltransferase gene in eucaryotic cells.
1986,
Pubmed Soussi,
Structural aspects of the p53 protein in relation to gene evolution.
1990,
Pubmed Soussi,
Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70.
1989,
Pubmed
,
Xenbase Stürzbecher,
Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells.
1987,
Pubmed Stürzbecher,
Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells.
1988,
Pubmed Subler,
Inhibition of viral and cellular promoters by human wild-type p53.
1992,
Pubmed Unger,
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.
1992,
Pubmed Wang,
The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen.
1989,
Pubmed Weintraub,
The MCK enhancer contains a p53 responsive element.
1991,
Pubmed Yew,
Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.
1992,
Pubmed Zambetti,
A comparison of the biological activities of wild-type and mutant p53.
1993,
Pubmed Zhang,
Adenovirus type 5 E3 gene products interfere with the expression of the cytolytic T cell immunodominant E1a antigen.
1991,
Pubmed
